Alzheimer’s disease is a debilitating neurological disorder of the brain that is treatable, but not preventable. A groundbreaking new vaccine – the first in clinical trials – will be tested at Beth Israel Deaconess Medical Center in Boston.
According to research by the CUMC Center for Alzheimer’s Disease Research, people can unknowingly over time become more susceptible to the deadly disease, which attacks the area of the brain called the hippocampus. Researchers believe there may be a link between the disease and the oxidation of red blood cells – known as stem cell oxidative stress.
The program, being tested on healthy volunteers, is called “reducing oxidative stress in the hippocampus-related cells.”
As an upside, the study is using a method called highly sensitive screening, which is different from traditional flu tests and helps identify much earlier in the development of the disease.
In the study, over 100 healthy adults between the ages of 36 and 61 will receive either a placebo or the nasal spray.
Researchers will then be able to compare how much blood they receive in one area to see how much they are exposed to the oxidation. If successful, doctors will be able to use the approach to reduce future incidence of Alzheimer’s disease.
If the vaccine performs as well as expected, research may move into later stage testing that tests the efficacy of a nasal spray in healthy adults.
The vaccine will be administered as part of an ongoing Alzheimer’s Alzheimer’s Disease Study in Boston, which will be completed in 2025.
The vaccine is currently owned by CTD Sciences.
The University of Massachusetts Medical School also has its own Alzheimer’s Disease Initiative to develop potential treatments for patients.